Aptabio Therapeutics Inc.

Rm A-0504 Heungdeok IT Valley Tower, Yongin, Gyeonggi, South Korea

Clinical Trials

2 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

55.6%

Phase 2

44.4%

Trial Status Distribution

Active, not recruiting

22.2%

Completed

33.3%

Recruiting

33.3%

Terminated

11.1%

Clinical Trials

Trials sponsored by this organization (9)

A Phase 1 Study of ABF-101 in Single- and Multiple-Ascending Doses

Phase 1

Recruiting

interventional

Feb 202668 participants

A Phase 1 Study of APX-343A as Monotherapy or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Phase 1

Recruiting

interventional

Oct 2025110 participants

Efficacy and Safety Study of Isuzinaxib in Subjects With DKD

Phase 2

Recruiting

interventional

May 2025186 participants

Study of APX-115 in Contrast Induced Acute Kidney Injury in Subjects Undergoing PCI

Phase 2

Completed

interventional

Dec 2023218 participants

A Phase 2 Study of APX-115 in Hospitalized Patients With Confirmed Mild to Moderate COVID-19.

Phase 2

Terminated

interventional

Oct 202116 participants

Safety, Tolerability and Renal Effects of APX-115 in Subjects With Type 2 Diabetes and Nephropathy

Phase 2

Completed

interventional

Aug 2020140 participants

A study investigating the tolerability and renal effects of investigational medicinal product APX-115 on patients with Type 2 Diabetes and Nephropathy

Phase 1

Active, not recruiting

Mar 2020140 participants

Multi-centre Study to Assess Safety, Tolerability and Renal Effects of APX-115 in Subjects with Type 2 Diabetes and Nephropathy

Phase 1

Active, not recruiting

Mar 2020140 participants

Page 1 of 2

Approvals

No approval data available

News

No news articles found

Back to Organizations